The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Open accessAbstract
The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade, with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a number of other commercially available drugs that have been studied for this indication. Although most of the US Food and Drug Administration (FDA)–approved drugs are antiangiogenic multikinase inhibitors—vandetanib, cabozantinib, sorafenib, lenvatinib—there are two FDA indications that are mutation specific—dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer. Furthermore, other mutation-specific drugs, immunotherapies, and novel strategies for advanced thyroid cancer are under investigation. Understanding the molecular basis of thyroid cancer, the drugs of interest for treatment of advanced thyroid cancer, and how these drugs can be administered safely and in the appropriate clinical scenario are the topics of this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Cabanillas, M. E., McFadden, D. G., & Durante, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30172-6 · Cited by 1,430
Self-citationGenomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
HAY, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., & Grant, C. S. (1993) · PubMed · Cited by 1,223
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Self-citationSelumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Xing, M., Liu, R., Liu, X., Murugan, A. K., Zhu, G., Zeiger, M. A., Pai, S., & Bishop, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5094 · Cited by 725
Ramsey, S., Blough, D., Kirchhoff, A., Kreizenbeck, K., Fedorenko, C., Snell, K., Newcomb, P., Hollingworth, W., & Overstreet, K. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1263 · Cited by 699
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Volante, M., Collini, P., Nikiforov, Y. E., Sakamoto, A., Kakudo, K., Katoh, R., Lloyd, R. V., LiVolsi, V. A., Papotti, M., Sobrinho-Simoes, M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180309e6a · Cited by 619
Highly prevalent TERT promoter mutations in aggressive thyroid cancers
Liu, X., Bishop, J., Shan, Y., Pai, S., Liu, D., Murugan, A. K., Sun, H., El-Naggar, A. K., & Xing, M. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0210 · Cited by 613
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 541
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Pozdeyev, N., Gay, L. M., Sokol, E. S., Hartmaier, R., Deaver, K. E., Davis, S., French, J. D., Borre, P. V., LaBarbera, D. V., Tan, A.-C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0373 · Cited by 533
Wells, S. A., Gosnell, J. E., Gagel, R. F., Moley, J., Pfister, D., Sosa, J. A., Skinner, M., Krebs, A., Vasselli, J., & Schlumberger, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6604 · Cited by 519
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S., Materazzi, G., Sellari-Franceschini, S., Ribechini, A., Torregrossa, L., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.76 · Cited by 483
Landa, I., Ganly, I., Chan, T. A., Mitsutake, N., Matsuse, M., Ibrahimpasic, T., Ghossein, R. A., & Fagin, J. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2383 · Cited by 462
Ryder, M., Ghossein, R. A., Ricarte-Filho, J. C. M., Knauf, J. A., & Fagin, J. A. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0036 · Cited by 443
Self-citationSun, Y., Niu, W., Du, F., Du, C., Li, S., Wang, J., Li, L., Wang, F., Hao, Y., Li, C., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0332-8 · Cited by 431
Carr, L. L., Mankoff, D. A., Goulart, B. H., Eaton, K. D., Capell, P. T., Kell, E. M., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 421
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 406
Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Self-citationBrose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 388
Self-citationPapillary and follicular thyroid cancer
Simpson, W. J., McKinney, S. E., Carruthers, J. S., Gospodarowicz, M. K., Sutcliffe, S. B., & Panzarella, T. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90758-3 · Cited by 382
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Lam, E. T., Ringel, M. D., Kloos, R. T., Prior, T. W., Knopp, M. V., Liang, J., Sammet, S., Hall, N. C., Wakely, P. E., Vasko, V. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0068 · Cited by 377
Rothenberg, S. M., McFadden, D. G., Palmer, E. L., Daniels, G. H., & Wirth, L. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2915 · Cited by 376
Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70335-2 · Cited by 375
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
Haddad, R. I., Nasr, C., Bischoff, L., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q.-Y., Ehya, H., Goldner, W., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0089 · Cited by 356
Lynch, T. J., Kim, E. S., Eaby, B., Garey, J., West, D. P., & Lacouture, M. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-610 · Cited by 341
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Wagle, N., Grabiner, B. C., Van Allen, E. M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., Gray, N., Barletta, J. A., Guo, Y., Swanson, S. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403352 · Cited by 321
Pryma, D. A., Chin, B. B., Noto, R. B., Dillon, J. S., Perkins, S. M., Sólnes, L. B., Kostakoğlu, L., Serafini, A. N., Pampaloni, M. H., Jensen, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217463 · Cited by 320
Liu, X., Qu, S., Liu, R., Sheng, C., Shi, X., Zhu, G., Murugan, A. K., Guan, H., Yu, H., Wang, Y., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4048 · Cited by 318
Hiltzik, D., Carlson, D. L., Tuttle, R. M., Chuai, S., Ishill, N., Shaha, A., Shah, J. P., Singh, B., & Ghossein, R. A. (2006) · Cancer · doi:10.1002/cncr.21739 · Cited by 312
Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B., & Roberts, D. D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2561 · Cited by 305
Kappers, M. H. W., van Esch, J. H. M., Sluiter, W., Sleijfer, S., Danser, A. H. J., & van den Meiracker, A. H. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.149690 · Cited by 284
Ganly, I., Makarov, V., Deraje, S., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G., Eng, S., Bose, P., Kuo, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.002 · Cited by 283
Kelly, L. M., Barila, G., Liu, P., Evdokimova, V. N., Trivedi, S., Panebianco, F., Gandhi, M., Carty, S. E., Hodak, S. P., Luo, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321937111 · Cited by 271
Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P., Livitz, D., Rosebrock, D., Sadow, P. M., Campbell, B., Donovan, S. E., Amin, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.013 · Cited by 263
Robinson, B. G., Paz-Ares, L., Krebs, A., Vasselli, J., & Haddad, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2461 · Cited by 257
Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Pacini, F., Ball, D. W., McCaffrey, J., Newbold, K., Allison, R., Martins, R. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1127 · Cited by 247
Self-citationSchlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx479 · Cited by 240
Cutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P., & Sekulic, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.032 · Cited by 237
Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M. E., Busam, K., Carvajal, R. D., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.1660 · Cited by 231
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer
Falchook, G. S., Millward, M., Hong, D., Naing, A., Piha-Paul, S., Waguespack, S. G., Cabanillas, M. E., Sherman, S. I., Ma, B., Curtis, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0123 · Cited by 227
Self-citationHAY, I. D., McConahey, W. M., & Goellner, J. R. (2002) · PubMed · Cited by 224
Mehnert, J. M., Varga, A., Brose, M. S., Aggarwal, R. R., Lin, C.-C., Prawira, A., de Braud, F., Tamura, K., Doi, T., Piha-Paul, S. A., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5380-3 · Cited by 215
Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced Cardiotoxicity
Chintalgattu, V., Rees, M. L., Culver, J. C., Goel, A., Jiffar, T., Zhang, J., Dunner, K., Pati, S., Bankson, J. A., Pasqualini, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005066 · Cited by 214
Kim, G., McKee, A. E., Ning, Y.-M., Hazarika, M., Theoret, M., Johnson, J. R., Xu, Q. C., Tang, S., Sridhara, R., Jiang, X., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0776 · Cited by 212
Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M. D., & Hurria, A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6472 · Cited by 200
Lenvatinib for Anaplastic Thyroid Cancer
Tahara, M., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, L., Toda, K., Enokida, T., Minami, H., Imamura, Y., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00025 · Cited by 198
Kim, K. B., Cabanillas, M. E., Lazar, A. J., Williams, M. D., Sanders, D. L., Ilagan, J. L., Nolop, K., Lee, R. J., & Sherman, S. I. (2013) · Thyroid · doi:10.1089/thy.2013.0057 · Cited by 197
Self-citationCabanillas, M. E., Schlumberger, M., Jarzab, B., Martins, R. G., Pacini, F., Robinson, B., McCaffrey, J. C., Shah, M. H., Bodenner, D. L., Topliss, D., et al. (2015) · Cancer · doi:10.1002/cncr.29395 · Cited by 186
Self-citationMeijer, J. A. A., Le Cessie, S., Van Den Hout, W. B., Kievit, J., Schoones, J. W., Romijn, J. A., & Smit, J. W. A. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03666.x · Cited by 180
Cutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P., & Sekulic, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.033 · Cited by 177
A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
Bible, K. C., Suman, V. J., Menefee, M. E., Smallridge, R. C., Molina, J. R., Maples, W. J., Karlin, N. J., Traynor, A. M., Kumar, P., Goh, B. C., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1520 · Cited by 175
Iten, F., Müller, B., Schindler, C., Rochlitz, C., Oertli, D., Mäcke, H. R., Müller-Brand, J., & Walter, M. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0935 · Cited by 170
Ultraviolet A and Photosensitivity during Vemurafenib Therapy
Dummer, R., Rinderknecht, J., & Goldinger, S. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1113752 · Cited by 166
Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma
Cabanillas, M. E., Ferrarotto, R., Garden, A. S., Ahmed, S., Busaidy, N. L., Dadu, R., Williams, M. D., Skinner, H., Gunn, G. B., Grosu, H., et al. (2018) · Thyroid · doi:10.1089/thy.2018.0060 · Cited by 159
Self-citationPatterns of Treatment Failure in Anaplastic Thyroid Carcinoma
Rao, S. N., Zafereo, M., Dadu, R., Busaidy, N. L., Hess, K. R., Cote, G. J., Williams, M. D., William, W. N., Sandulache, V. C., Gross, N. D., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0395 · Cited by 154
Self-citationRen, Z.-G., Zhu, K.-S., Kang, H., Lu, M.-Q., Qu, Z., Lu, L., Song, T.-Q., Zhou, W.-P., Wang, H., Yang, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9651 · Cited by 152
Ryder, M. M., Gild, M. L., Hohl, T. M., Pamer, E. G., Knauf, J. A., Ghossein, R. A., Joyce, J. A., & Fagin, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054302 · Cited by 149
Self-citationLim, S., Chang, H. K., Yoon, M. J., Hong, Y. K., Kim, H., Chung, W. Y., Park, C. S., Nam, K., Kang, S., Kim, M. K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt379 · Cited by 147
Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine
Jaber, T., Waguespack, S. G., Cabanillas, M. E., Elbanan, M., Vu, T. H., Dadu, R., Sherman, S. I., Amit, M., Santos, E. B., Zafereo, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00612 · Cited by 146
Self-citationDuBois, S. G., Laetsch, T. W., Federman, N. C., Turpin, B. K., Albert, C. M., Nagasubramanian, R., Anderson, M. E., Davis, J. L., Qamoos, H., Reynolds, M. E., et al. (2018) · Cancer · doi:10.1002/cncr.31701 · Cited by 138
Chintakuntlawar, A. V., Rumilla, K. M., Smith, C. Y., Jenkins, S. M., Foote, R. L., Kasperbauer, J. L., Morris, J. C., Ryder, M. M., Alsidawi, S., Hilger, C. R., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3756 · Cited by 137
Self-citationvon Moos, R., Thuerlimann, B., Aapro, M., Rayson, D., Harrold, K., Sehouli, J., Scotté, F., Lorusso, D., Dummer, R., Lacouture, M. E., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.028 · Cited by 134
Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
Reyes-Habito, C. M., & Roh, E. K. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.04.013 · Cited by 132
Dadu, R., Shah, K. B., Busaidy, N. L., Waguespack, S. G., Habra, M. A., Ying, A. K., Hu, M. I.-N., Bassett, R. L., Jiménez, C., Sherman, S. I., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2246 · Cited by 131
Self-citationCabanillas, M. E., de Souza, J. A., Geyer, S. M., Wirth, L. J., Menefee, M. E., Liu, S. V., Shah, K. B., Wright, J., & Shah, M. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0226 · Cited by 130
Self-citationKiyota, N., Schlumberger, M. J., Muro, K., Ando, Y., Takahashi, S., Kawai, Y., Wirth, L. J., Robinson, B. G., Sherman, S. I., Suzuki, T., et al. (2015) · Cancer Science · doi:10.1111/cas.12826 · Cited by 127
Kappers, M. H. W., de Beer, V. J., Zhou, Z., Danser, A. H. J., Sleijfer, S., Duncker, D. J., van den Meiracker, A. H., & Merkus, D. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.182220 · Cited by 124
Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer
Prasongsook, N., Kumar, A., Chintakuntlawar, A. V., Foote, R. L., Kasperbauer, J. L., Molina, J. R., Garces, Y. I., Ma, D. J., Wittich, M. A. N., Rubin, J., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01180 · Cited by 123
Self-citationHanna, G. J., Busaidy, N. L., Chau, N. G., Wirth, L. J., Barletta, J. A., Calles, A., Haddad, R. I., Kraft, S., Cabanillas, M. E., Rabinowits, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2297 · Cited by 123
Self-citationBible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Karlin, N. J., Sideras, K., Morris, J. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3713 · Cited by 120
Ravaud, A., de la Fouchardière, C., Caron, P. J., Doussau, A., Cao, C. D., Asselineau, J., Rodien, P., Pouessel, D., Nicolli-Sire, P., Klein, M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.029 · Cited by 115
Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
Choe, C. H., McArthur, G. A., Caro, I., Kempen, J. H., & Amaravadi, R. K. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.003 · Cited by 113
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Sun, Y., Du, F., Gao, M., Ji, Q., Li, Q., Zhang, Y., Guo, Z., Wang, J., Chen, X., Wang, J., et al. (2018) · Thyroid · doi:10.1089/thy.2018.0022 · Cited by 113
Blevins, D. P., Dadu, R., Hu, M. I.-N., Baik, C. S., Balachandran, D. D., Ross, W., Gunn, G. B., & Cabanillas, M. E. (2013) · Thyroid · doi:10.1089/thy.2012.0598 · Cited by 112
Self-citationSorafenib in metastatic thyroid cancer
Capdevila, J., Iglesias, L., Halperín, I., Segura, Á., Martínez‐Trufero, J., Salgado, M. Á. V., Corral, J., Obiols, G., Grande, E., Grau, J. J., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0351 · Cited by 112
Gunda, V., Gigliotti, B. J., Ndishabandi, D., Ashry, T., McCarthy, M., Zhou, Z., Amin, S., Freeman, G. J., Alessandrini, A., & Parangi, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0296-2 · Cited by 111
Kappers, M. H. W., van Esch, J. H. M., Smedts, F. M. M., de Krijger, R. R., Eechoute, K., Mathijssen, R. H. J., Sleijfer, S., Leijten, F. P. J., Danser, A. H. J., van den Meiracker, A. H., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1172 · Cited by 108
Drilon, A. E. D. C., Subbiah, V., Oxnard, G. R., Bauer, T. M., Velcheti, V., Lakhani, N. J., Besse, B., Park, K., Patel, J. D., Cabanillas, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.102 · Cited by 104
Self-citationEffect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Lin, E. H., Morris, J. S., & Ayers, G. D. (2002) · PubMed · Cited by 101
Prolonged duration of response in lenvatinib responders with thyroid cancer
Gianoukakis, A. G., Dutcus, C. E., Batty, N., Guo, M. D., & Baig, M. A. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0049 · Cited by 96
EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC
Krishnamoorthy, G. P., Davidson, N. R., Leach, S. D., Zhao, Z., Lowe, S. W., Lee, G., Landa, I., Nagarajah, J., Saqcena, M., Singh, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0606 · Cited by 94
Schneider, T., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H. A. J., Roozen, C. F. M., Bos, M., Corver, W. E., van Wezel, T., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2525 · Cited by 91
A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
Cabanillas, M. E., Brose, M. S., Holland, J. S., Ferguson, K. C., & Sherman, S. I. (2014) · Thyroid · doi:10.1089/thy.2014.0125 · Cited by 89
Self-citationManagement of Medullary Thyroid Carcinoma
Jiménez, C., Hu, M. I.-N., & Gagel, R. F. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.03.001 · Cited by 89
Shah, M. H., Wei, L., Wirth, L. J., Daniels, G. A., de Souza, J. A., Timmers, C. D., Sexton, J., Beshara, M., Nichols, D., Snyder, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.6022 · Cited by 85
Sandulache, V. C., Williams, M. D., Lai, S. Y., Lu, C., William, W. N., Busaidy, N. L., Cote, G. J., Singh, R. R., Luthra, R., & Cabanillas, M. E. (2016) · Thyroid · doi:10.1089/thy.2016.0076 · Cited by 84
Self-citationOneal, P. A., Kwitkowski, V. E., Luo, L., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0295 · Cited by 79
Macedo, L. T., Lima, J. P. N., dos Santos, L. V., & Sasse, A. D. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2129-z · Cited by 78
Nam, S. H., Bae, M. R., Roh, J., Gong, G., Cho, K., Choi, S., Nam, S. Y., & Kim, S. Y. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.11.003 · Cited by 75
Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications
Nostrand, D. V. (2018) · Thyroid · doi:10.1089/thy.2018.0048 · Cited by 74
Erratum: Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A. E. D. C., Hu, Z. I., Lai, G. G. Y., & Tan, D. S.-W. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.188 · Cited by 74
Sherman, E. J., Dunn, L. A., Ho, A. L., Baxi, S. S., Ghossein, R. A., Fury, M. G., Haque, S. S., Sima, C. S., Cullen, G. D., Fagin, J. A., et al. (2017) · Cancer · doi:10.1002/cncr.30861 · Cited by 73
CirculatingBRAFV600Ein the Diagnosis and Follow-Up of Differentiated Papillary Thyroid Carcinoma
Pupilli, C., Pinzani, P., Salvianti, F., Fibbi, B., Rossi, M., Petrone, L., Perigli, G., Feo, M. L. D., Vezzosi, V., Pazzagli, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1072 · Cited by 72
BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity
Cabanillas, M. E., Patel, A. P., Danysh, B. P., Dadu, R., Kopetz, S., & Falchook, G. S. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0207-9 · Cited by 71
Self-citationDemetri, G. D., Paz-Ares, L. G., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C. M., Krauss, J. C., Sigal, D. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.017 · Cited by 71
Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell–Derived Thyroid Carcinomas
Xu, B., Ibrahimpašić, T., Wang, L., Sabra, M. M., Migliacci, J. C., Tuttle, R. M., Ganly, I., & Ghossein, R. A. (2016) · Thyroid · doi:10.1089/thy.2016.0247 · Cited by 69
Ilias, Ι., Divgi, C. R., & Pacák, K. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.03.003 · Cited by 66
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
Draganova, D., Kerger, J., Caspers, L., & Willermain, F. (2015) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-015-0049-9 · Cited by 62
A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor Vandetanib
Giacchero, D., Ramacciotti, C. F., Arnault, J. P., Brassard, M., Baudin, É., Maksimovic, L., Mateus, C., Tomasic, G., Wechsler, J., Schlumberger, M. J., et al. (2012) · Archives of Dermatology · doi:10.1001/2013.jamadermatol.192 · Cited by 60
Reversal of Cushing's Syndrome by Vandetanib in Medullary Thyroid Carcinoma
Baudry, C., Paepegaey, A. C., & Groussin, L. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1301428 · Cited by 60
Uveitis in Patients With Late-Stage Cutaneous Melanoma Treated With Vemurafenib
Guedj, M., Quéant, A., Funck‐Brentano, E., Kramkimel, N., Lellouch, J., Monnet, D., Longvert, C., Gantzer, A., & Brézin, A. P. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.3024 · Cited by 58
Bikas, A., Kundra, P., Desale, S. Y., Mete, M., O'Keefe, K., Clark, B. G., Wray, L., Gandhi, R., Barett, C., Jelinek, J. S., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0930 · Cited by 58
Bisschop, C., ter Elst, A., Bosman, L. J., Platteel, I., Jalving, M., van den Berg, A., Diepstra, A., van Hemel, B. M., Diercks, G. F. H., Hospers, G. A. P., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000421 · Cited by 58
Management of treatment-related toxicities in advanced medullary thyroid cancer
Brose, M. S., Bible, K. C., Chow, L. Q. M., Gilbert, J., Grande, C., Worden, F. P., & Haddad, R. I. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.007 · Cited by 57
Treglia, G., Tamburello, A., & Giovanella, L. (2017) · HORMONES · doi:10.14310/horm.2002.1756 · Cited by 55
Zimmerman, E. I., Gibson, A. A., Hu, S., Vasilyeva, A., Orwick, S. J., Du, G., Mascara, G. P., Ong, S. S., Chen, T., Vogel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0694 · Cited by 53
Smith, A. L., Williams, M. D., Stewart, J., Wang, W., Krishnamurthy, S., Cabanillas, M. E., & Roy‐Chowdhuri, S. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21992 · Cited by 51
Self-citationAn open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
Lim, S. M., Chung, W. Y., Nam, K., Kang, S., Lim, J. Y., Kim, H., Shin, S. H., Sun, J.-M., Kim, S.-G., Kim, J.-H., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.020 · Cited by 50
Nella, A. A., Lodish, M. B., Fox, E., Balis, F. M., Quezado, M., Whitcomb, P. O., Derdak, J., Kebebew, E., Widemann, B. C., & Stratakis, C. A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4340 · Cited by 50
Schneider, T., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H. A. J., van Wezel, T., van Eijk, R., Morreau, H. M., Guchelaar, H., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/348124 · Cited by 48
Lassen, U., Albert, C. M., Kummar, S., van Tilburg, C. M., Dubois, S. G., Geoerger, B., Mascarenhas, L., Federman, N. C., Schilder, R. J., Doz, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy279.397 · Cited by 46
Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma
Bianchi, L., Rossi, L., Tomao, F., Papa, A., Zoratto, F., & Tomao, F. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0201 · Cited by 45
Uveitis as a Result of MAP Kinase Pathway Inhibition
Joshi, L., Karydis, A., Gemenetzi, M. K., Shao, E. H., & Taylor, S. R. J. (2013) · Case Reports in Ophthalmology · doi:10.1159/000357060 · Cited by 43
Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
Herrmann, J. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0514-0 · Cited by 43
Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy
Chen, F. W., Tseng, D., Reddy, S. A., DAUD, A. I., & Swetter, S. M. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.838 · Cited by 42
ROS1 Rearrangement in Thyroid Cancer
Ritterhouse, L. L., Wirth, L. J., Randolph, G. W., Sadow, P. M., Ross, D. S., Liddy, W., & Lennerz, J. K. (2016) · Thyroid · doi:10.1089/thy.2016.0101 · Cited by 34
Cutaneous manifestations of nontargeted and targeted chemotherapies
Shi, V. J., Levy, L., & Choi, J. N. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.018 · Cited by 32
Cebollero, A., Puértolas, T., Pajares, I., Calera, L., & Antón, A. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.978 · Cited by 30
CirculatingBRAFV600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
Iyer, P. C., Cote, G. J., Hai, T., Gule-Monroe, M. K., Bui, J. H., Williams, M. D., Hess, K. R., Hofmann, M.-C. C., Dadu, R., Zafereo, M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00173 · Cited by 28
Self-citationRecent advances and emerging therapies in anaplastic thyroid carcinoma
Cabanillas, M. E., Zafereo, M., Williams, M. D., Ferrarotto, R., Dadu, R., Gross, N. D., Gunn, G. B., Skinner, H. D., Cote, G. J., Grosu, H. B., et al. (2018) · F1000Research · doi:10.12688/f1000research.13124.1 · Cited by 25
Self-citationKeam, B., Kreitman, R. J., Wainberg, Z. A., Cabanillas, M. E., Cho, D. C., Italiano, A., Stein, A., Cho, J. Y., Schellens, J. H. M., Wen, P. Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy302.002 · Cited by 21
Self-citationShah, R. R. (2017) · Drug Safety · doi:10.1007/s40264-017-0508-3 · Cited by 20
Cutaneous complications of molecular targeted therapy used in oncology.
Lupu, I., Voiculescu, N., Bacalbașa, N., Cojocaru, I., Vrancian, V., & Giurcăneanu, C. (2016) · PubMed Central · Cited by 17
Fussey, J. M., Bryant, J., Batis, N., Spruce, R. J., Hartley, A. G. J., Good, J. S., McCabe, C. J., Boelaert, K., Sharma, N., & Mehanna, H. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00132 · Cited by 17
Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer
Fabbro, E. D., Dev, R., Cabanillas, M. E., Busaidy, N. L., Rodriguez, E. C., & Bruera, E. D. (2012) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000022 · Cited by 13
Self-citationPhototoxic Reaction Induced by Pazopanib
Udompanich, S., Chanprapaph, K., & Rajatanavin, N. (2018) · Case Reports in Dermatology · doi:10.1159/000494611 · Cited by 12
Bible, K. C., Ain, K. B., & Rosenthal, M. S. (2014) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.24 · Cited by 8
de Souza, J. A., Grogan, R. H., & Aschebrook-Kilfoy, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.3_suppl.17 · Cited by 2
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019
Maniakas, A., Dadu, R., Busaidy, N. L., Wang, J. R., Ferrarotto, R., Lu, C., Williams, M. D., Gunn, G. B., Hofmann, M.-C., Cote, G., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3362 · Cited by 382
Self-citationSubbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.014 · Cited by 357
Self-citationManiakas, A., Zafereo, M., & Cabanillas, M. E. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.020 · Cited by 80
Self-citationXie, J., Liu, J., Zhao, M., Li, X., Wang, Y., Zhao, Y., Cao, H., Ji, M., Chen, M., & Hou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043418 · Cited by 29
Metadata
- Authors
- Cabanillas, M. E., Ryder, M., & Jimenez, C.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-07-19
- Volume
- 40
- Issue
- 6
- Pages
- 1573-1604
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2966674226
- Cited by
- 335
- References
- 158
- FWCI
- 23.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.